Preparing for a New Wave of mRNA Technologies

BillionPhotos.com/Stock.adobe.com

The ability of the biopharma industry to meet the worldwide demand for messenger RNA vaccines was facilitated by contract development and manufacturing organizations. These partners promptly adapted their facilities and capabilities specifically for vaccine production, offering contract fill/finish and cold chain services required to meet demand. Examining the lessons learned from the COVID-19 pandemic, this article provides a perspective on the strategies and tactics taken to deliver a better drug development program and highlights the importance of remembering key lessons as the industry moves toward an era of new drug modalities.

Read this article in Pharmaceutical Technology’s February 2023 Outsourcing Innovation eBook.

About the author

Jeong Jin-hyeok is a lead specialist in drug product at Samsung Biologics.

Article Details

Pharmaceutical Technology
eBook: Outsourcing Innovation, February 2023
February 2023
Pages: 30–32

Citation

When referring to this article, please cite it as J. Jin-hyeok, “Preparing for a New Wave of mRNA Technologies," Pharmaceutical Technology Outsourcing Innovation eBook (February 2023).